Table 5

Clinical and genetic data of carefully selected neuroblastoma samples that were included in this study

Sample number

Lab number

% Tumor cells

Stage

MYCN amp

Ploidy

Adrenal localisation

Age

Dead/alive

Overall survival (months)

Type

NB1

01T15

80

4S

No

Tri

Yes

< 1 year

Alive

61.4

Favorable

NB2

98T33

95

1

No

Tri

Yes

< 1 year

Alive

76.9

Favorable

NB3

96T82

90

1

No

Tri

Yes

< 1 year

Alive

115.5

Favorable

NB4

99T129

90

1

No

Tri

Yes

< 1 year

Alive

71.7

Favorable

NB5

01T28

90

4

Yes

Di

Yes

> 1 year

Dead

5.6

Unfavorable

NB6

03T304

100

3^a

No

Di

Abdominal

> 1 year

Alive

12.0

Unfavorable

NB7

03T236

90

4

No

ND

Yes

> 5 year

Dead

19.4

Unfavorable

NB8

00T54

70

1

No

Tri

Yes

< 1 year

Alive

62.6

Favorable

NB9

00T35

> 95

4

Yes

Di

Yes

< 1 year

Dead

13.7

Unfavorable

NB10

99T125

80

3

No

Di

Yes

> 5 year

Alive

79.3

Unfavorable

NB11

92W145

70

4

No

ND

ND

> 5 year

Dead

19.5

Unfavorable

NB12

02T192

100

4

Yes

Di

Abdominal

> 5 year

Dead

16.2

Unfavorable

NB13

D031

> 95

4

No

Di

Abdominal

> 1 year

Dead

64.8

Unfavorable

NB14

E002

> 80

4

No

ND

Abdominal

> 1 year

Alive

65.7

Unfavorable

NB15

E037

> 80

4

No

ND

Abdominal

> 1 year

Alive

45.3

Unfavorable

NB16

E044

> 80

4

No

ND

Yes

< 1 year

Alive

37.0

Unfavorable

NB17

E121

> 80

4

Yes

ND

Abdominal

> 1 year

Dead

78.4

Unfavorable

NB18

04T121

60

3

Yes

Di

Yes

> 1 year

Dead

6

Unfavorable

Based on stage, MYCN amplification, ploidy, and age at diagnosis, samples were subdivided into favorable or unfavorable type.

^aNeuroblastoma or ganglioneuroblastoma. ND, not determined or unknown.

De Preter et al. Genome Biology 2006 7:R84   doi:10.1186/gb-2006-7-9-r84